# U.S. Department of Justice Issues Final Order Rescheduling Medical Cannabis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/final-order-rescheduling-medical-cannabis-schedule-iii/ > **Published:** 2026-04-23T21:11:08-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:14:06-04:00 > **Clinical Summary:** The DOJ's final order rescheduling medical cannabis to Schedule III removes federal barriers and opens new research pathways. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Federal Policy[Cannabis Research](https://cedclinic.com/pediatric-cannabis-certification-care-children/)Regulatory ChangeClinical PracticeDea Scheduling Why This Matters Rescheduling cannabis from Schedule I to Schedule III removes the federal barrier that has prevented rigorous [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) for decades. This regulatory change creates pathways for FDA-approved studies and standardized [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) that could finally generate the high-quality evidence base [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) desperately needs. Clinical Summary The Department of Justice has issued a final order moving cannabis from Schedule I (no accepted medical use) to Schedule III (accepted medical use with moderate dependence potential), aligning federal policy with extensive state-level medical cannabis programs. Schedule III classification places cannabis alongside substances like ketamine and anabolic steroids, allowing for medical use under physician supervision while maintaining controlled substance protections. This change removes research barriers that have limited clinical investigation since the Controlled Substances Act of 1970, though state-level regulations and clinical practice guidelines remain unchanged in the immediate term. Dr. Caplan’s Take “After treating hundreds of thousands of patients with cannabis, I’ve long argued that federal scheduling should reflect clinical reality rather than political history. This rescheduling doesn’t change what works for patients today, but it opens doors for the rigorous research that will help us practice better medicine tomorrow.” Clinical Perspective 🧠 Clinicians should expect expanded research opportunities and eventual FDA guidance, but current state medical cannabis programs and clinical protocols remain valid. Patients using medical cannabis under state programs will see no immediate changes to access or legality. The real impact will emerge over years as researchers can finally conduct the controlled trials needed to establish dosing guidelines, drug interactions, and evidence-based protocols. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20U.S.%20Department%20of%20Justice%20Issues%20Final%20Order%20Rescheduling%20Medical%20Cannabis%20to%20S...%20%40drcaplan&url=https%3A//vicentellp.com/press/doj-issues-final-order-rescheduling-medical-cannabis-to-schedule-iii-restoring-clinical-integrity-to-federal-policy/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//vicentellp.com/press/doj-issues-final-order-rescheduling-medical-cannabis-to-schedule-iii-restoring-clinical-integrity-to-federal-policy/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20U.S.%20Department%20of%20Justice%20Issues%20Final%20Order%20Rescheduling%20Medical%20Cannabis%20to%20S...%20--%20via%20%40drcaplan.bsky.social%20https%3A//vicentellp.com/press/doj-issues-final-order-rescheduling-medical-cannabis-to-schedule-iii-restoring-clinical-integrity-to-federal-policy/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://vicentellp.com/press/doj-issues-final-order-rescheduling-medical-cannabis-to-schedule-iii-restoring-clinical-integrity-to-federal-policy/](https://vicentellp.com/press/doj-issues-final-order-rescheduling-medical-cannabis-to-schedule-iii-restoring-clinical-integrity-to-federal-policy/) Table of Contents - [FAQ](#FAQ)[What is the CED Clinical Relevance rating system?](#What_is_the_CED_Clinical_Relevance_rating_system) - [What areas does this cannabis news update cover?](#What_areas_does_this_cannabis_news_update_cover) - [Why is this classified as “Notable Clinical Interest”?](#Why_is_this_classified_as_8220Notable_Clinical_Interest8221) - [What type of organization is CED Clinic?](#What_type_of_organization_is_CED_Clinic) - [How should healthcare providers use this type of clinical relevance information?](#How_should_healthcare_providers_use_this_type_of_clinical_relevance_information) - [Related](#Related) ## FAQ #### What is the CED Clinical Relevance rating system? The CED Clinical Relevance system appears to be a classification method that rates clinical findings by importance. Rating #76 indicates “Notable Clinical Interest” for emerging findings or policy developments that warrant close monitoring. #### What areas does this cannabis news update cover? This update covers four key areas: Federal Policy, [Cannabis Research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), Regulatory Change, and Clinical Practice. These categories suggest comprehensive coverage of cannabis-related developments affecting healthcare professionals. #### Why is this classified as “Notable Clinical Interest”? Items with this classification represent emerging findings or policy developments that are worth monitoring closely by healthcare professionals. This suggests the content contains important but developing information that may impact clinical practice. #### What type of organization is CED Clinic? Based on the clinical relevance ratings and cannabis news focus, CED Clinic appears to be a medical organization that tracks and analyzes cannabis-related clinical developments. They seem to specialize in providing healthcare professionals with relevant cannabis research and policy updates. #### How should healthcare providers use this type of clinical relevance information? Healthcare providers should use this as a monitoring tool for emerging cannabis-related developments that may impact patient care. The rating system helps prioritize which developments require closer attention and potential integration into clinical practice. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Trump’s DOJ Issues New Rescheduling Order – CRB Monitor News Explore the details of the DOJ's new rescheduling order and its impact on [medical cannabis research](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/) and policy. Read More [Trump reclassifies state-licensed medical marijuana as less dangerous Schedule III drug](https://cedclinic.com/federal-marijuana-reclassification-clinical-research/) Learn how the Trump administration reclassified medical marijuana, easing restrictions and expanding research potential. [Learn More](https://cedclinic.com/federal-marijuana-reclassification-clinical-research/) [How the reclassification of medical marijuana could impact Maryland dispensaries and researchers](https://cedclinic.com/maryland-medical-marijuana-dispensary-impact-reclassification/) Understand the local effects of federal reclassification on dispensaries and research in Maryland. [Discover More](https://cedclinic.com/maryland-medical-marijuana-dispensary-impact-reclassification/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).